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Background: The only subgroups of patients with heart failure and atrial fibrillation in which the efficacy of cardiac
resynchronization therapy has been scientifically proven are patients with indications for right ventricular pacing
and patients after atrioventricular junction ablation. However it is unlikely that atrioventricular junction ablation
would be a standard procedure in the majority of the heart failure patients with cardiac resynchronization therapy
and concomitant atrial fibrillation due to the irreversible character of the procedure and a spontaneous sinus
rhythm resumption that occurs in about 10% of these patients.
Methods/Design: Pilot-CRAfT is the first randomized controlled trial evaluating the efficacy of a rhythm control
strategy in atrial fibrillation patients with cardiac resynchronization therapy devices. The aim of this prospective, single
center randomized controlled pilot study is to answer the question whether the patients with cardiac resynchronization
therapy and permanent atrial fibrillation would benefit from a strategy to restore and maintain sinus rhythm (that is
‘rhythm control’ strategy) in comparison to rate control strategy. The study population consists of 60 patients with
heart failure and concomitant long-standing persistent or permanent atrial fibrillation who underwent a cardiac
resynchronization therapy device implantation at least 3 months before qualification. Study participants are randomly
assigned to the rhythm control strategy (including electrical cardioversion and pharmacotherapy) or to the rate control
group whose goal is to control ventricular rate. The follow-up time is 12 months. The primary endpoint is the ratio of
effectively captured biventricular beats. The secondary endpoints include peak oxygen consumption, six-minute walk
test distance, heart failure symptom escalation, reverse remodelling of the heart on echo and quality of life.
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Randomized controlled trialBackground
The heart failure (HF) patients with concomitant atrial
fibrillation (AF) make up a significant subgroup of patients
eligible for cardiac resynchronization therapy (CRT) but
their treatment remains problematic.
The prevalence of AF as well as chronic HF is significant
and it is still growing. It has been estimated that 1 to
2% of population suffers from AF - the most common
form of sustained arrhythmia [1]. The prevalence of HF
in general population is 1 to 2% and rises with age,
reaching >10% in a subpopulation of subjects aged 70
years or older [2]. The coexistence of AF and HF is very
frequent. Both illnesses may negatively influence and
promote each other [1]. The coexistence of AF in HF
patients is related to the severity of heart failure. The
prevalence of AF in New York Heart Association (NYHA)
class I is about 5%, reaching 25 to 50% in NYHA III/IV
subgroups [3,4]. About 23% of patients undergoing a
CRT device implantation in Europe have AF [5]. With
population ageing, estimated growth in the prevalence
of AF and HF and broad label of CRT implantation, the
issue of proper treatment of CRT patients with AF becomes
crucial.
Nevertheless, the CRT in patients with AF encounters
many problems and its beneficial effect in this group of
patients is not fully established. The indications for
CRT arise from the evidence coming from the studies
where AF patients were absent or barely present. The
only subgroup of patients with AF in which beneficial
effect of CRT is scientifically proven (that is proven in
randomized controlled trails (RCTs)) are the patients
with concomitant indications for right ventricular pacing
[6,7]. As a result, the present indications for the CRT in
patients with concomitant AF stem from the recommen-
dations for those in sinus rhythm (SR), having a level of
evidence C in IIb class [2]. Moreover, there is no sufficient
data evaluating the CRT impact on mortality in the AF
patients and an emphasis is put on the lack of trials
comparing the rhythm control versus rate control strategy
in this group of patients [2,5].
Contrary to the widening range of patients with HF
suitable for CRT, the evidence is growing that the benefit
of resynchronization in the subgroup of patients with
AF is reduced. The initial meta-analyses of the studies
comparing the efficacy of CRT in patients with AF ver-
sus SR suggested similar effect of response to CRT in
the AF group in terms of NYHA functional class orejection fraction and lower effect on the exercise tolerance
improvement measured by means of six-minute walk test
(6MWT) [8,9]. The recent and larger meta-analysis has
shown however, that the patients with AF have higher
mortality and higher rate of non-response to CRT than
their SR counterparts [10]. Whatever the results of those
systematic reviews, it should be mentioned that the vast
majority of the data included in those analysis has been
derived from observational studies - not randomized trials,
which are not available.
The lower effectiveness of CRT in AF patients is ex-
plained by the irregular and unpredictable character of
ventricular beats in this arrhythmia which lowers the
ratio of effectively biventricular paced captured beats
(BiVp%). This hypothesis is corroborated by studies of
AF patients on CRT undergoing atrioventricular junction
ablation (AVJA), which enables the BiVp% to be close
to 100%. According to the registries, the CRT efficacy
in patients with AF undergoing AVJA is similar to that
in patients in SR, whereas the patients with AF but no
AVJA seem not to benefit from resynchronization at all,
even if BiVp% exceeds 85% [3,11]. As a result, the estimated
BiVp% that guarantees the CRT efficacy is ≥95% [11] or
even ≥98 to 99% [5,12,13]. The most recent ESC guidelines
put an emphasis on the achievement of biventricular cap-
ture as close as possible to 100% and - unless achieved - on
performing AVJA [5]. Nevertheless, the significant group of
AF patients with already-implanted CRT devices present
with this goal not sufficiently met.
Although AVJA seems to provide the efficacy of CRT
[2,5,7,14], it is unlikely that performing an iatrogenic III°
atrioventricular block will be recommended in all patients
with AF undergoing CRT implantation. Such an approach
would generate an enormous group of pacemaker-
dependent patients - a potentially dangerous situation.
Moreover, performing an AVJA seems questionable,
bearing in mind the spontaneous SR resumption that
occurs in 10 to 25% of the CRT patients with permanent/
long-standing persistent AF [15,16]. This phenomenon
may occur even a few years after the implantation of CRT
device [16]. Due to the limitations of the AVJA, the strat-
egy of SR resumption and its maintenance seems to be a
reasonable option in the group of CRT patients with AF.
To the authors’ best of knowledge, a randomized, pro-
spective trial assessing the influence of rhythm control
strategy on CRT efficacy in AF patients has not yet been
performed. The only trial upon this issue was the non-
Table 1 The inclusion and the exclusion criteria for the
Pilot-CRAfT study
Inclusion criteria:
1) Permanent or long-standing persistent AF (definitions according to
the latest ESC guidelines on AF)
2) At least three months after the procedure of a CRT device
implantation
3) A CRT device with the presence of a right atrial electrode
4) Age: ≥18 years old
5) Effectively biventricular paced captured beats percentage <95%
6) Effective therapy with oral anticoagulants for at least three weeks
7) Written informed consent
Exclusion criteria:
1) Reversible causes of AF
2) Significant valve disease
3) Advanced AV block (including: AVJA)
4) Contraindications to amiodarone (hyperthyroidism, non-
compensated hypothyroidism, drug intolerance, QT >460 ms for
men, QT >450 ms for women)
5) Long-QT syndrome
6) Cardiac transplantation in six months
7) Life expectancy less than one year
8) LA diameter larger than 6 cm
9) Heart failure decompensation within 48 hours before the
qualification
10) Chronic dialysis
11) History of alcohol abuse
12) Pregnancy or lack of effective contraceptive therapy (in case of
females in the reproductive age)
13) Participation in other clinical trial
AF, atrial fibrillation; AV, atrioventricular; AVJA, atrioventricular junction
ablation; CRT, cardiac resynchronization therapy; ESC, European Society of
Cardiology; LA, left atrium.
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shown a positive effect on end-diastolic volume in the
rhythm control group, whereas the influence on ejection
fraction was comparable between the rhythm and the
rate control groups.
The promising results of the rhythm control strategy
were also achieved in the PABA-CHF trial which com-
pared pulmonary vein isolation (PVI) versus the ablate
and pace strategy (that is performing an AVJA + CRT-D
(CRT with defibrillator function) implantation) in HF
patients with paroxysmal or persistent/permanent AF [18].
During the 6-month observation the patients who under-
went PVI had longer 6MWT distance, higher ejection frac-
tion and they claimed better quality of life. The effect was
even more profound in the permanent/persistent AF sub-
group. The trial did not prove any favorable impact of
rhythm control strategy on mortality and showed a higher
hospitalization rate in this group; however, it analyzed the
overall group HF and AF patients, not the subgroup meet-
ing the current CRT-D implantation criteria and compared
the PVI alone (that is not combined with CRT) has in
comparison to the patients treated with CRT +AVJA.
Methods/Design
The aim of the study
The aim of the study is to answer the question whether
the patients with permanent or long-standing persistent
AF on cardiac resynchronization therapy due to heart
failure will benefit from the treatment strategy to resume
and maintain sinus rhythm in terms of achievement of
adequate BiVp%. An additional goal of the study is the
identification of potential factors predicting the efficacy/
the lack of benefit of the rhythm control strategy. As it is
a pilot study, its other goal is to collect data which would
enable the authors to design another, larger study, which
would have a power to examine the influence of a rhythm
control strategy versus rate control strategy on the mortal-
ity and morbidity of HF in this group of patients.
Study scheme
The Pilot-CRAfT study is a single-center, open, prospect-
ive, randomized controlled trial. The trial enrolls 60
patients with HF and concomitant permanent or long-
standing persistent AF who underwent CRT implantation
at least three months before the enrollment in the Second
Department of Coronary Artery Disease of the Institute of
Cardiology in Warsaw, Poland. The inclusion and exclu-
sion criteria are listed in the Table 1. Before the enroll-
ment each participant will give written, informed consent.
Principles of the management of the patients (treatment
strategies)
The enrolled patients are randomly assigned to one of
the two groups (in a 1:1 ratio). In the first group, astrategy to restore and maintain SR is implemented (that
is rhythm control strategy - the active treatment group).
In the second group, a strategy to slow ventricular rate
will be implemented (that is rate control strategy - the
control group).
Rhythm control group
The basic method to restore and maintain sinus rhythm
comprises a combination of pharmacological antiarrhyth-
mic treatment and external electrical cardioversion (EEC).
The attempts to restore SR must not be performed unless
the patient has been treated effectively with oral anticoag-
ulants for at least three weeks.
The pharmacological treatment consists of amiodarone
administered orally. The loading dose of amiodarone is up
to 600 mg daily for the first 4 weeks. Then, a mainten-
ance dose of 200 mg/daily is administered (a dose may
be adjusted at discretion of treating physician). The
Ciszewski et al. Trials 2014, 15:386 Page 4 of 9
http://www.trialsjournal.com/content/15/1/386loading dose may be modified or omitted, especially, if a
patient had been given amiodarone before the enrollment.
If any contraindications to amiodarone occur during the
treatment, it must be discontinued promptly. The use of
other antiarrhythmic agents is possible unless they are
contraindicated.
A basic tool to restore SR in the trial is an EEC. The first
EEC should be performed after the complete loading
dose of amiodarone has been administered (unless SR
is restored spontaneously). Up to three shocks during one
cardioversion are allowed. The amount of the energy
delivered is left to discretion of a physician performing the
EEC. If AF recurs, the patient should undergo the next
EEC as soon as possible but preserving the safety time
margins of effective anticoagulation period (at least three
weeks). The maximal number of EEC procedures is three
and the third one is possible only if AF recurs no earlier
than three weeks after the second EEC and SR resumption
is related to alleviation of HF symptoms. If SR resumption
or its maintenance is impossible or AF recurs after the
third EEC, a strategy of rhythm control is discontinued
and a rate control strategy is implemented.
In patients undergoing the rhythm control strategy
treatment, a procedure of ablation of AF substrate (that
is PVI) is possible. The decision to offer the patient an
ablation must be made collectively at the discretion of
the therapeutic team. Routinely in the trial, a PVI pro-
cedure is allowed and offered to patients responding to
EEC after the second recurrence of AF.
Rate control group - control group
The treatment goal in the rate control group (that is the
control group) is to slow and control ventricular rate by
means of pharmacological antiarrhythmic agents and
AVJA as to achieve satisfactory BiVp%. The pharmacother-
apy should include negative chronotropes and negative
dromotropic drugs such as beta-blockers, digitalis and
amiodarone (the use of other, less popular agents, is also
possible). It should be consistent with the current guide-
lines of treatment of HF and AF. The choice of the agents
and its’ dosage is left to discretion of the treating physician.
An AVJA procedure in this group of patients is possible but
not obligatory. The decision to perform AVJA is left to the
discretion of the treating physician. An effective anticoagu-
lant treatment is essential in both groups.
Follow-up
The follow-up period is 12 months. The patients are
scheduled for control visits every three months. Every
control visit consists of: a standard review of a device and
treatment; an assessment of the actual BiVp%; the ques-
tions concerning the occurrence of the analyzed endpoints
and a standard 12-lead ECG. Additionally, on the qualifi-
cation visit, and control visits after 3 and 12 months, a6MWT, an echocardiograph and a cardiopulmonary
exercise test (CPX) are performed and the patients are
asked to fill the questionnaire about their quality of
live, that is the Minnesota Living with Heart Failure
Questionnaire (MLHFQ), © University of Minnesota
[19,20], (MLHF contact information and permission to
use: MAPI Research Trust, Lyon, France. Email: PROin-
formation@mapi-trust.org - Internet: www.mapi-trust.org
and University of Minnesota. Email: mlhfq@umn.edu -
Internet www.mlhfq.org). Moreover, a thyroid-stimulating
hormone (TSH) level control is performed on the qualifi-
cation visit and during visits after six and twelve months.
Endpoints
All of the endpoints will be assessed in two timeframes:
at three months and one year from the baseline examin-
ation timeframe.
The primary endpoint is an overall BiVp% during the
one-year study period (that is a mean BiVp% through
the whole follow-up period). The ‘triggered’ paced beats
are not treated as effective and are excluded from the
analysis.
The secondary endpoints are listed in the Table 2.
Based on the results of the primary endpoint, the
authors plan to perform a preliminary identification of
the factors predicting the response to the rhythm control
strategy.
Methodology of additional examinations and tests
Device control
Device interrogation is performed on every control visit.
It should include: a standard battery and lead control,
analysis of the histograms, alerts (especially arrhythmic),
history of the ‘mode switch’ episodes (in order to evaluate
AF burden) and BiVp% (measured from the last control
visit). In case of CRT-D devices, the episodes of arrhythmia
as well as the number of adequate and inadequate high-
voltage intervention should be registered. If required,
necessary modifications in the identification and treatment
of ventricular arrhythmias should be made.
Moreover, during the visit a review of pharmacological
treatment is performed, including analysis of its efficacy,
validity, and occurrence of adverse effects. If required,
necessary modifications in the pharmacological treat-
ment, an eventual decision to change the rhythm control
for the rate control or a decision to perform AVJA
should be made. If an intervention of a device occurs,
the additional device control should be performed.
Echocardiography
Participants will undergo an echo test (Philips Matrix
iE33, Philips Ultrasound, Bothell, WA, USA) performed
with a general assessment of morphology and function
of the heart.
Table 2 Secondary endpoints of the Pilot-CRAfT trial
Secondary endpoints:
BiVp%:
• BiVp% change from baseline.
Physical competence:
• 6MWT distance
• Peak oxygen uptake (peak VO2) in CPX
• NYHA functional class
The echocardiographic assessment of the reverse remodelling:
• Increase in left ventricle ejection fraction (LVEF)
• Decrease in left ventricle diastolic diameter and volume (LVEDD, LVEDV)
• Decrease in left ventricle systolic diameter and volume (LVESD, LVESV),
• Decrease in size of the left atrium (LA)
• Decrease of the severity of mitral insufficiency
Quality of life:
• Measured with the Minnesota Living with Heart Failure Questionnaire
Clinical endpoints:
• Unplanned hospitalizations due to heart failure exacerbations
• Death
• Cardiovascular death
• Hospitalizations due to cardiovascular causes
• Stroke/TIA
• A combined endpoint including unplanned hospitalizations due to cardiovascular causes or death
Heart arrhythmias:
• AF - using mode switch to measure time of AF with fast ventricular rate
• Ventricular tachycardia including torsade de pointes tachycardia and ventricular fibrillation
In the CRT-D subgroup:
• Number of adequate and inadequate shocks (separately)






The clinical endpoints, the occurrence of heart arrhythmias and adverse events are collected for safety measures. All of the endpoints will be assessed at
three-months and one-year from the baseline timeframes.
6MWT, six-minute walk test; AF, atrial fibrillation; AVJA, atrioventricular junction ablation; BiVp%, effectively biventricular paced captured beats percentage;
CPX, cardiopulmonary exercise test; CRT-D, cardiac resynchronization therapy with defibrillator function; TIA, transient ischemic attack.
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 Cardiac dimensions (including diameter, area and
volume of left atrium)
 Left ventricular global systolic function (EF% and
volumes, dp/dt), left ventricular regional function
(extent and localization of infarct scar) and left
ventricle diastolic function
 Type of diastolic dysfunction, diastolic pressure in
the left ventricle Presence and severity of valvular diseases
(particularly mitral regurgitation)
 Evaluation of cardiac dyssynchrony
 Intraventricular dyssynchrony parameters
('septal flash' and septal to posterior wall
motion delay, septal to lateral time to peak
systolic point from R-wave on electrocardiogram
(Ts) delay)
 Atrioventricular dyssynchrony: diastolic filling ratio
(LVFT/RR)
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left ventricular and right ventricular pre-ejection
time in pulsed-wave Doppler and/or a delay between
the onset of systolic motion in the basal right
ventricular free wall versus the most delayed basal
LV segment in tissue Doppler)
In patients with sinus rhythm, an AV interval will be
optimized (unless optimization had been performed
previously).Cardiopulmonary exercise test
CPXs on a treadmill (Marquette T2000, GE Healthcare,
Little Chalfont, UK) with standardized modified Bruce
or Naughton exercise protocols will be applied. Breath-
to-breath respiratory gas analysis will be carried out with
Vmax Encore 29c equipment (Viasys Healthcare, San
Diego, CA, USA). An exercise test will be carried out
until maximal patient’s exertion, maximal heart rate or
dangerous ventricular arrhythmia occurs. The following
parameters will be monitored during CPX:
 Heart rate, arterial blood pressure, ST segment
changes
 Peak oxygen uptake (peak VO2, ml/kg/minute,
l/minute)
 Peak VO2 as percentage of normalized VO2 in given
population
 Peak carbon dioxide exhalation (peak VCO2, l/minute)
 Oxygen pulse (O2 pulse, ml/heart rate)
 Maximal minute ventilation (VE, l/minute)
 Breathing reserve (BR): maximal voluntary
ventilation/maximal exertional ventilation × 100%
 Heart rate reserve (HRR): maximal HR/peak
exertional HR × 100%
 Anaerobic threshold level (ml/kg/minute)
 Maximal CO2 equivalent: VE/VCO2 max
 VE/VCO2 slope and VE/VO2 slope
 Subjective dyspnea level (according to Borg scale
from 1 to 5, where 5 is maximal dyspnea)
Exertional level will be assessed subjectively by patients
in Borg scale (6 to 20, where 6 means no exertion, 20 -
maximal exertion).Statistical methods
Sample size
The calculation of a sample size was made based on the
estimated results in the groups for the primary endpoint
(BiVp%) and the following assumptions: 1) the mean
difference of BiVp% between groups would be 8% and
standard deviation (SD): 15%; 2) probability of a type I
error: 0.05; 3) probability of a type II error: 20%; 4) thetype of test: Student’s two-sample t-test; 5) drop-out
rate: 8%.
A power analysis revealed that a minimum of 30 pa-
tients per group will be required to assure at least 80%
power for detecting the anticipated between-group dif-
ferences in BiVp% and to compensate for the expected
drop-out rate.
Randomization
Randomization will be provided by independent statisti-
cian using SAS 9.2 software (SAS Institute Inc., Cary, NC,
USA). Permuted block randomization will be used (blocks
AB and BA). Once an eligible patient gives his informed
consent, he will be given a specific, unique identifier. The
statistician will monitor the enrollment process.
Data management
During the study, the investigators will regularly fill in
the case report forms (CRF). Database management and
quality control for the study will be performed by an
independent statistician. Structured data elements from
the CRFs will be entered into the database and reviewed
using double data entry for verification. Information
entered into the database will be systematically checked
and evident errors will be corrected. All of the omissions
and/or questions concerning the data will be discussed
with the investigator in order to preserve the completeness
of the database.
Statistical analysis
Baseline demographic characteristic and clinical variables
will be summarized for each arm of the study. Continuous
data will be presented as arithmetic means and SD for
normally distributed variables or as medians and inter-
quartile ranges (25 to 75th) for abnormally distributed var-
iables. Normality will be tested by the Shapiro-Wilk test.
Comparison of two groups will be based on parametric
Student’s two-sample t-test, or Cochran-Cox test or non-
parametric Mann–Whitney test as appropriate. Student’s
paired t- or Wilcoxon’s test will be used to compare con-
tinuous variable differences between baseline and the end
of observation period.
Categorical data will be given as absolute and relative
frequencies (percentages). The differences in proportions
between them will be examined using the chi-square - test
with Yates’s correction or Fisher’s exact test as appropriate.
A logistic regression model will be used to identify
independent predictors of response to therapy. For the
longitudinal analysis, curves of cumulative probability of
events will be constructed according to the Kaplan-Meier
method, and the cumulative events rates will be compared
by the log-rank test. A Cox proportional hazards regres-
sion analysis will be performed to assess for any potential
influence of covariates. The assumptions of the Cox
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spection of the log-log survival function by time curve.
Due to the possibility of the treatment crossovers, all
major treatment comparisons between the randomized
group in this trial will be performed according to both
the intention-to-treat and the per protocol principles.
All null hypothesis will be two-tailed with a 0.05 type I
error rate.
Statistical analysis will be performed using the SAS 9.2
statistical package (SAS Institute Inc., Cary, NC, USA).
The investigation conforms with the principles out-
lined in the Declaration of Helsinki [21]. The local ethics
committee (that is the Ethics Committee of the Institute
of Cardiology, Warsaw, Poland) has approved the study
protocol including the written informed consent form
(approval number: IK-NP-0021-47/1378/13).
Discussion
Based on the current knowledge, the authors assume
that the rhythm control strategy would be at least as
good as the rate control strategy in terms of BiVp%. The
achievement of SR and satisfactory BiVp% in the rhythm
control group may strengthen the underestimated pos-
ition of cardioversion in the group of HF patients on
CRT with concomitant permanent AF.
It may seem disputable whether the CRT patients with
permanent AF will resume and maintain SR. As has
been already mentioned, HF and AF are diseases that
can negatively influence each other. In at least some of
the patients, an occurrence of AF seems to be a marker
of HF severity. We hypothesize that restoration of sinus
rhythm, which would enhance the performance of CRT
and enable better treatment of HF, may have beneficial
effect on AF progression. Based on the evidence of the
SR resumption phenomenon [13] and the study by
Turco et al., this is highly probable. In the latter work it
has been proven that - by means of a single cardiover-
sion - SR is resumed in 82% of the patients and main-
tained for a 1 year in about 60% of the former AF-CRT
patients [14]. We assume that the possibility of additional
cardioversions and standard use of the amiodarone will
elevate this percentage. Additionally, the results of the
PVI isolation from the PABA-CHF trial in HF patients
with AF are also appealing bearing in mind the initial
differences between the populations of the PABA-CHF
and our study (that is the lack of CRT in the PVI sub-
group and paroxysmal character of the AF in half of the
patients). After a 6-month observation period, 88% and
71% of patients who underwent PVI were free from AF
depending on whether they received or did not receive
antiarrhythmic agents [18].
The authors are fully aware that during the progres-
sion of HF, irreversible fibrous changes within the atria
occur which promote AF and its maintenance [22], so itis unlikely that the proposed treatment strategy would
be effective in all of the patients included. Hence, it seems
crucial not only to establish the efficacy of proposed treat-
ment strategy of rhythm control but also to define the
subgroup of patients who would benefit the most from
this strategy. An attempt to perform preliminary analysis
of the non-responders as well as the ultra-responders
would be made in the trial.
The standard use of amiodarone in both of the groups
may seem disputable in the potential complications of
this treatment and limited evidence of its efficacy.
However, following the literature the use of amiodarone
should facilitate sinus rhythm maintenance in the
rhythm control group [1,23,24]. The use of the drug in
the rate control group arises from its beneficial effect on
AV node in this group of patients [1]. Moreover, it makes
two of the treating arms more consistent. Following the
latest ESC guidelines on management of AF [1], amioda-
rone is commonly used in patients with AF and depressed
left ventricle ejection fraction and its potential adverse
events, occurring in up to about 10% of patients according
to the latest RCT comparing amiodarone with dronedar-
one [24], will be carefully monitored, including regular
TSH measurements, QT evaluation and occurrence of
arrhythmias at baseline visits and during the follow-up
period.
One of the limitations of the trial is the number of the
participants which surely has an impact on the statistical
strength of the study. It would enable the researchers
to assess the efficacy of the two treatment strategies on
the primary endpoint only. The statistical difference
within the clinical secondary endpoints of this study
will be difficult to achieve. However, the lack of sufficient
data about the CRT in the patients with concomitant AF
necessitates the undertaking of an initial pilot study upon
this issue.
The incoming results of the Pilot-CRAfT would enable
the authors to prepare a parallel larger, well-designed
multi-center study assessing the influence of both treat-
ment strategies on ‘harder’ clinical endpoints, such as
mortality and morbidity, as well as further analysis of
the factors determining the response to the rhythm
control strategy. The assessment of the efficacy of the
rhythm control strategy in CRT and AF patients and the
identification of the subgroup of patients who benefit
from it the most would create an alternative to the cur-
rently recommended rate control strategy which has some
considerable limitations.
Whatever the results of the trial, performing a prospect-
ive, randomized study on CRT patients with concomitant
persistent forms of AF would finally provide strong
scientific evidence data about the efficacy of CRT in
this specific subgroup of patients. This urgently needed
data has been long awaited.
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